bozitinib + crizotinib

This is a combination of two small molecule tyrosine kinase inhibitors, bozitinib and crizotinib. Crizotinib is an approved targeted therapy for cancers with specific genetic alterations, notably ALK-positive or ROS1-positive non-small cell lung cancer (NSCLC). It acts by inhibiting several receptor tyrosine kinases including anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor (HGFR/c-MET), ROS1, and Recepteur d'Origine Nantais (RON), thereby blocking signaling pathways that promote tumor cell proliferation and survival[2][4][6]. Bozitinib is also a small molecule tyrosine kinase inhibitor; however, there is no evidence in the provided sources or current literature that "bozitinib" as a distinct drug exists or has been studied in combination with crizotinib. The only documented combinations involving crizotinib are with other agents such as erlotinib or palbociclib[1][3]. Therefore, this entry describes the theoretical combination based on known properties of crizotinib.